Hyperfine Net Income Over Time
| HYPR Stock | USD 1.17 0.03 2.63% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Hyperfine Performance and Hyperfine Correlation. Hyperfine | Build AI portfolio with Hyperfine Stock |
Can Health Care Equipment & Supplies industry sustain growth momentum? Does Hyperfine have expansion opportunities? Factors like these will boost the valuation of Hyperfine. Market participants price Hyperfine higher when confident in its future expansion prospects. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Hyperfine demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Earnings Share (0.52) | Revenue Per Share | Quarterly Revenue Growth (0.06) | Return On Assets | Return On Equity |
The market value of Hyperfine is measured differently than its book value, which is the value of Hyperfine that is recorded on the company's balance sheet. Investors also form their own opinion of Hyperfine's value that differs from its market value or its book value, called intrinsic value, which is Hyperfine's true underlying value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Because Hyperfine's market value can be influenced by many factors that don't directly affect Hyperfine's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Hyperfine's value and its price as these two are different measures arrived at by different means. Investors typically determine if Hyperfine is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Hyperfine's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Cross Equities Net Income Analysis
Compare Hyperfine and related stocks such as InspireMD, Vivani Medical, and Avita Medical Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NSPR | (3.8 K) | (17.6 M) | (17.6 M) | (29.3 M) | (25.1 M) | (15.6 M) | (8.5 M) | (8.4 M) | (7.2 M) | (10 M) | (10.5 M) | (14.9 M) | (18.5 M) | (19.9 M) | (32 M) | (28.8 M) | (27.4 M) |
| VANI | (16.3 M) | (16.3 M) | (16.3 M) | (23 M) | (35.2 M) | (20 M) | (33.2 M) | (28.5 M) | (35.1 M) | (33.6 M) | (9.3 M) | (12.8 M) | (13.9 M) | (25.7 M) | (23.5 M) | (27 M) | (28.4 M) |
| RCEL | (225.5 K) | (7.6 M) | (8.1 M) | (5.1 M) | (7.9 M) | (10.3 M) | (11.5 M) | (17.2 M) | (24.6 M) | (24.6 M) | (24.6 M) | (25.1 M) | (26.7 M) | (35.4 M) | (61.8 M) | (48.6 M) | (46.2 M) |
| FONR | (7.5 M) | 5.8 M | 8.7 M | 10.4 M | 12.9 M | 15.7 M | 19.6 M | 21.2 M | 15.3 M | 8.2 M | 10.2 M | 12.4 M | 9.4 M | 10.6 M | 8.3 M | 9.6 M | 10.1 M |
| EDAP | 181.8 K | (938 K) | (7.5 M) | (5 M) | (512 K) | (1.7 M) | 3.8 M | (681 K) | (338 K) | 1.5 M | (1.7 M) | 700 K | (2.9 M) | (21.2 M) | (19 M) | (17.1 M) | (16.3 M) |
| LUNG | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.9 M) | (2.8 M) | (2.8 M) | (5.4 M) | (18.5 M) | (20.7 M) | (32.2 M) | (48.7 M) | (58.9 M) | (60.8 M) | (56.4 M) | (50.8 M) | (48.2 M) |
| CNTB | (24 M) | (24 M) | (24 M) | (24 M) | (24 M) | (24 M) | (24 M) | (24 M) | (24 M) | (24 M) | (120.3 M) | (205.2 M) | (116.4 M) | (59.5 M) | (15.6 M) | (18 M) | (18.9 M) |
| QNCX | (12.2 M) | (12.2 M) | (12.2 M) | (12.2 M) | (12.2 M) | (12.2 M) | (12.2 M) | (12.2 M) | (12.5 M) | (37 M) | (76.8 M) | (89.9 M) | (51.7 M) | (31.4 M) | (56.8 M) | (51.1 M) | (53.7 M) |
| QIPT | (34.1 K) | (548 K) | (2.5 M) | (1.4 M) | (18.3 M) | (57.4 M) | (19.2 M) | 14.5 M | (5.6 M) | (4.6 M) | (6.2 M) | 4.8 M | (2.8 M) | (6.8 M) | (10.7 M) | (9.6 M) | (9.1 M) |
| IMA | (40.9 M) | (40.9 M) | (40.9 M) | (40.9 M) | (40.9 M) | (40.9 M) | (40.9 M) | (40.9 M) | (40.9 M) | (16.8 M) | (44.3 M) | (34.1 M) | (68.8 M) | (68.2 M) | (36.6 M) | (32.9 M) | (34.6 M) |
Hyperfine and related stocks such as InspireMD, Vivani Medical, and Avita Medical Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Hyperfine financial statement analysis. It represents the amount of money remaining after all of Hyperfine operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Hyperfine | HYPR |
Specialization | Health Care, Health Care Equipment & Services |
| Business Address | 351 New Whitfield |
| Exchange | NASDAQ Exchange |
USD 1.17
Additional Tools for Hyperfine Stock Analysis
When running Hyperfine's price analysis, check to measure Hyperfine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hyperfine is operating at the current time. Most of Hyperfine's value examination focuses on studying past and present price action to predict the probability of Hyperfine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hyperfine's price. Additionally, you may evaluate how the addition of Hyperfine to your portfolios can decrease your overall portfolio volatility.